PatentsGlobal
Tasrif Pharmaceutical Secures Second U.S. Patent for CD155-Targeting Antibody Developed with Abzena’s Humanisation Technology
Tasrif Pharmaceutical, in collaboration with Abzena, has been granted a second U.S. patent covering its proprietary humanised monoclonal antibodies targeting the Poliovirus Receptor (CD155). This patent complements Tasrif’s foundational IP and supports a broad pipeline of next-generation immunotherapies, including TSR…
Tuesday, August 4, 2026